Publications

Publications

At Bayer, we are working in collaboration with the leading scientific, academic, and community partners to improve our understanding of cardiorenal diseases.  

 

We invite you to explore Bayer-supported publications pertaining to heart failure with a focus on LVEF ≥ 40%. This library is not intended to serve as a comprehensive repository of all publications. Publications not supported by Bayer are not included. Access to the full text of publications may depend on journal access rights.

 

To help narrow down your search, choose the relevant tags and click apply. Applying multiple tags will narrow your results.

 

Last updated “September 15, 2024”.

Types of Enhancements Available

audio
Audio
infographic
Infographic
PLS
Plain Language Summary
video
Video
other
Others

To help narrow down your search, select the relevant filters from the dropdowns and Click Apply

Hold down Ctrl key on keyboard to select multiple years

Total available publications: 19    

Filtered results: 19

Finerenone in heart failure and chronic kidney disease with type 2 diabetes: The FINE-HEART pooled analysis of cardiovascular, kidney, and mortality outcomes

Vaduganathan M, et al. Nat Med. 2024;doi:10.1038/s41591-024-03264-4

Vaduganathan M, 01 09 2024

Finerenone in heart failure with mildly reduced or preserved ejection fraction

Solomon SD, et al. N Engl J Med. 2024;doi:10.1056/NEJMoa2407107

Solomon SD, 01 09 2024

Mineralocorticoid receptor antagonists in heart failure: An individual patient level meta-analysis

Jhund PS, et al. Lancet. 2024;doi:10.1016/S0140-6736(24)01733-1

Jhund PS, 01 09 2024

Long-term outcomes of heart failure with preserved or mid-range ejection fraction in the United States

Sun LA, et al. JACC Adv. 2024;3(7):101027.

Sun LA, 01 07 2024

Baseline characteristics of patients with heart failure with mildly reduced or preserved ejection fraction: The FINEARTS-HF trial

Solomon SD, et al. Eur J Heart Fail. 2024;26(6):1334-1346.

Solomon SD, 01 05 2024

Cardiovascular-kidney-metabolic overlap in heart failure with mildly reduced or preserved ejection fraction: A trial-level analysis

Ostrominski JW, et al. J Am Coll Cardiol. 2024;84(2):223-228.

Ostrominski JW, 01 05 2024

Finerenone in patients with heart failure with mildly reduced or preserved ejection fraction: Rationale and design of the FINEARTS-HF trial

Vaduganathan M, et al. Eur J Heart Fail. 2024;26(6):1324-1333.

Vaduganathan M, 01 05 2024

Gamified behavioral science intervention to enhance trial enrollment: An embedded study within the FINEARTS-HF trial

Bhatt AS, et al. J Am Coll Cardiol HF. 2024;doi:10.1016/j.jchf.2024.05.002.

Bhatt AS, 01 05 2024

Generalizability of the spectrum of kidney risk in the FINEARTS-HF trial to US adults with heart failure

Ostrominski JW, et al. J Card Fail. 2024;S1071-9164(24)00156-8.

Ostrominski JW, 01 05 2024

Management of heart failure with reduced ejection fraction in patients with diabetes mellitus and chronic kidney disease

Khan MS, et al. Semin Nephrol. 2023;43(3):151429.

Khan MS, 01 10 2023